Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has 7 years of Operating Leases data on file, last reported at $671000.0 in Q2 2025.

• Operating Leases for Q2 2025 came in at $671000.0, down 89.35% year-over-year; the trailing twelve-month figure through Jun 2025 was $671000.0 (down 89.35% YoY), and the FY2024 annual result was $3.5 million, down 60.36% from the prior year.
• Operating Leases fell to $671000.0 in Q2 2025 per AKBA's latest filing, from $7.6 million in the prior quarter.
• Over five years, Operating Leases peaked at $35.3 million in Q3 2022 and troughed at $671000.0 in Q2 2025.
• A 5-year average of $18.8 million and a median of $17.9 million in 2021 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases surged 40.53% in 2022, then tumbled 89.35% in 2025.
• A 5-year view of Operating Leases shows it stood at $33.7 million in 2021, then dropped by 14.07% to $29.0 million in 2022, then tumbled by 69.11% to $8.9 million in 2023, then slumped by 60.36% to $3.5 million in 2024, then plunged by 81.08% to $671000.0 in 2025.
• Business Quant data shows AKBA's Operating Leases at $671000.0 in Q2 2025, $7.6 million in Q1 2025, and $3.5 million in Q4 2024.